Richard Johnson is a professor of medicine at the University of Colorado School of Medicine. His research focuses on metabolic and renal health, with a particular emphasis on the physiological roles and health impacts of fructose and uric acid. His published work covers chronic kidney disease, podocyte injury, cardiovascular risk factors, and the effects of heat stress and diet on metabolic conditions.
While most of the brain takes up glucose independently of insulin, glucose uptake in specific regions such as the hippocampus and hypothalamus requires insulin.
"the brain has certain areas that are insulin dependent and the brain has some areas that are not. So much of the brain does not require insulin for glucose uptake, but there's certain regions that do, and one of them is the hippocampus, the hypothalamus" (said at 0:09:30)
Most brain glucose uptake is mediated by the insulin-independent transporters GLUT1 (in endothelial cells and glia) and GLUT3 (in neurons). Certain brain regions, including the hippocampus, hypothalamus, and cerebellum, also express the insulin-sensitive glucose transporter GLUT4 and insulin receptors. In these regions, insulin stimulates GLUT4 translocation to increase glucose uptake and metabolic flux (e.g., during cognitive processing or metabolic regulation). However, basal glucose transport in the hippocampus and hypothalamus is still mediated by GLUT1 and GLUT3 and does not strictly require insulin for baseline survival or function.
Fructose blocks insulin-mediated glucose uptake in the hippocampus, which impairs memory acutely and chronically leads to local insulin resistance, mitochondrial dysfunction, glycolysis, and inflammation.
"what fructose does is it blocks the effects of insulin to take up glucose in the hippocampus, and that kind of dampens the memory and allows the animal to feel that it can go into a dangerous area... And acutely that's okay because it makes you be able to forage, but chronically it results in basically an insulin resistance to this area where the cells are not getting enough fuel, there's mitochondrial dysfunction, a shift to glycolysis, which is a shift away from the mitochondria, the development of inflammation." (said at 0:10:00)
The speaker describes the 'fructose survival hypothesis' (developed primarily by Dr. Richard Johnson and colleagues), which posits that cerebral fructose metabolism evolved to promote foraging by transiently suppressing hippocampal metabolism and memory, while chronic overactivation causes local insulin resistance, mitochondrial dysfunction, a shift toward glycolysis, neuroinflammation, and cognitive impairment. While preclinical rodent studies and mechanistic reviews support these downstream pathological features (mitochondrial oxidative stress, hippocampal insulin signaling impairment, and neuroinflammation), the evolutionary framing regarding acute dampening of hippocampal function to promote risk-taking foraging remains a theoretical hypothesis rather than an established clinical fact in humans.
- supports: Cerebral Fructose Metabolism as a Potential Mechanism Driving Alzheimer's Disease. (Frontiers in aging neuroscience 2020) · cited 70x in the literature
"The fall in energy from fructose metabolism stimulates foraging and food intake while reducing energy and oxygen needs by decreasing mitochondrial function, stimulating glycolysis, and inducing insulin resistance." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Mindful Eating: A Deep Insight Into Fructose Metabolism and Its Effects on Appetite Regula… (Journal of nutrition and metabolism 2025) · cited 7x in the literature
"Chronic high fructose intake has been linked to mitochondrial dysfunction, increased production of reactive oxygen species (ROS), and neuroinflammation, all of which contribute to cognitive decline and impairments in memory and learning. Additionally, fructose-induced alterations in insulin signaling in the brain are associated with increased risk for neurodegenerative diseases." (abstract, results, passage verified)
pubmedfull study (doi)
A study from the University of Alabama by Dr. Singh showed that uric acid-lowering drugs like allopurinol protect against Alzheimer's disease in a dose-dependent manner.
"I think in your book you quote this beautiful study from the University of Alabama by Dr. Singh, where you point out that taking drugs that lower uric acid, like allopurinol, actually were found to protect against Alzheimer's. So having a low uric acid protects against Alzheimer's, and you actually pointed it out that the paper showed that the dose matters: the higher the dose of allopurinol, which lowers uric acid, was associated with more protection than others." (said at 0:17:00)
A 2018 observational Medicare cohort study led by Dr. Jasvinder A. Singh at the University of Alabama at Birmingham evaluated urate-lowering therapy and incident dementia. The study found that compared to low-dose allopurinol (<200 mg/day), higher allopurinol doses (200-299 mg/day and ≥300 mg/day) were associated with a dose-dependent decrease in the risk of incident dementia (HR 0.80 and 0.59, respectively). However, the study evaluated all-cause incident dementia using administrative billing codes rather than adjudicated Alzheimer's disease specifically, and its observational design demonstrates statistical association rather than proven causal protection.
When blood glucose levels rise above 120 mg/dL, the polyol pathway begins converting glucose into fructose.
"when your glucose levels start going up over 120, you start making fructose from it, and you're also stimulating insulin." (said at 0:50:45)
The speaker accurately describes the biochemical mechanism whereby elevated blood glucose increases flux through the polyol pathway (via aldose reductase and sorbitol dehydrogenase) to produce endogenous fructose, which concurrently stimulates insulin secretion. However, describing this as an on/off switch occurring specifically when glucose exceeds 120 mg/dL simplifies a continuous biochemical concentration gradient. Aldose reductase has a relatively high Km (low affinity) for glucose compared to hexokinase; consequently, polyol pathway flux increases progressively across rising postprandial or hyperglycemic glucose concentrations rather than abruptly activating at a strict threshold of 120 mg/dL.